PRODUCTS IN DEVELOPMENT
More, healthier years with your pet
We’re developing drugs that target the underlying causes of aging.
Kirby
Newfoundland
LOY-001
Intended to extend lifespan and healthspan for large and giant breed dogs
Interested in getting your dog involved in upcoming clinical studies? Be the first to know.
Proof-of-concept
Pilot studies
Companion dog clinical study
FDA approval
Inky
Age 4
ABOUT
Large and giant breed dogs have average life expectancies that are only half that of the smallest breeds. LOY-001 targets the biological mechanisms thought to cause this lifespan disparity.
THE PRODUCT
A long-acting product administered to your dog by their veterinarian every three to six months.
EST LAUNCH — CONDITIONAL APPROVAL
2027*
Proof-of-concept
Pilot studies
Companion dog clinical study
FDA approval
*FDA approval not guaranteed
LOY-002
Intended to extend lifespan and healthspan for older dogs of all but the smallest breeds
Interested in getting your dog involved in upcoming clinical studies? Be the first to know.
Proof-of-concept
Pilot studies
Companion dog clinical study
FDA approval
Charlie
Age 11
ABOUT
LOY-002 is being developed to support healthy aging in older dogs of nearly every size and breed. The product is thought to improve metabolic fitness, which would extend the number of healthy years your dog lives.
THE PRODUCT
Designed as a daily pill for your dog, prescribed by your veterinarian.
NEXT STEPS
We’re now launching our STAY study — the largest clinical study of its kind. Learn more about the study and whether your dog may qualify to enroll.
EST LAUNCH — CONDITIONAL APPROVAL
2025*
Proof-of-concept
Pilot studies
Companion dog clinical study
FDA approval
*FDA approval not guaranteed
LOY-003
Intended to extend lifespan and healthspan for large and giant breed dogs
Interested in getting your dog involved in upcoming clinical studies? Be the first to know.
Proof-of-concept
Pilot studies
Companion dog clinical study
FDA approval
Kirby
Age 5
ABOUT
Large and giant breed dogs have average life expectancies that are only half that of the smallest breeds. As with LOY-001, our LOY-003 product targets the biological mechanisms thought to cause this lifespan disparity.
THE PRODUCT
Designed as a daily pill for your dog, prescribed by your veterinarian.
EST LAUNCH — CONDITIONAL APPROVAL
2027*
Proof-of-concept
Pilot studies
Companion dog clinical study
FDA approval
*FDA approval not guaranteed
Our guiding principles
01
Safety comes first, always.
We take our responsibility to pets, pet parents, and veterinarians very seriously. Above all, our work is driven by our commitment to safety and responsible science.
02
Collaboration breeds genius.
Our research is powered by a fundamental collaboration between the top aging scientists, veterinarians, and engineers across a variety of specialties, with a shared purpose of constant innovation to develop the first-ever longevity drugs.
03
Optimize for availability.
We’re dedicated to developing effective preventive treatments that are convenient and easy for veterinarians and pet parents alike. We constantly strive to maximize product availability and remove barriers in pet healthcare.
GET INVOLVED
Participate in our clinical trials to help us develop the first dog aging drugs.
Our team at Loyal is pioneering new research focused on understanding and treating the underlying causes of aging in dogs with our products.
Veterinarians
Discover how participating in our clinical trials can help dogs and benefit your practice.
Partner with us
Dog owners
Join our list for product announcements and opportunities to participate in clinical studies.